Compare PFSA & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFSA | INAB |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.6M |
| IPO Year | N/A | 2021 |
| Metric | PFSA | INAB |
|---|---|---|
| Price | $0.07 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $108.00 |
| AVG Volume (30 Days) | ★ 10.6M | 664.6K |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 122.22 | N/A |
| 52 Week Low | $0.07 | $1.17 |
| 52 Week High | $12.76 | $12.53 |
| Indicator | PFSA | INAB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 66.12 |
| Support Level | N/A | $1.17 |
| Resistance Level | N/A | $1.87 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 96.26 |
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.